Skip to content

EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures

EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures (EPVent2)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01681225
Acronym
EPVent2
Enrollment
202
Registered
2012-09-07
Start date
2012-10-31
Completion date
2018-10-19
Last updated
2019-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome

Keywords

ARDS, mechanical ventilation, ALI, esophageal pressure

Brief summary

This phase II multi-centered, randomized controlled trial of mechanical ventilation directed by esophageal pressure measurement will test the primary hypothesis that using a strategy of maintaining a minimal but positive transpulmonary pressure (Ptp = airway pressure minus pleural pressure) throughout the ventilatory cycle will lead to an improvement in patient survival.

Detailed description

This phase II prospective randomized controlled trial of ventilation directed by esophageal pressure measurements will enroll 200 patients with moderate to severe ARDS by the Berlin conference definition in several academic medical centers in North America. The control group will be ventilated using an alternative high-PEEP strategy with PEEP and FiO2 set using to an empiric table. Plasma samples will be obtained at enrollment and days 3 and 7 and assessed for a variety of lung injury biomarkers to better assess the association between our intervention and the inflammation associated with mechanical ventilation and the development of ARDS. Hospital survivors will undergo a brief follow up phone survey to assess survival, functional status (Barthel Index), health-related QOL (Short Form 12), and frailty (VES) twelve months after enrollment. The study length will be six years with a six month start-up period followed by a planned 50 month enrollment and twelve month follow-up.

Interventions

OTHEREsophageal-pressure guided mechanical ventilation
OTHERHigh PEEP mechanical ventilation

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
Beth Israel Deaconess Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Acute onset of ARDS as defined by the Berlin Consensus Conference definitions: 1. Hypoxemic respiratory failure with PaO2 / FIO2 ratio \< 200 mmHg 2. b) Bilateral alveolar/interstitial infiltrates on chest x-ray, with opacities not present for more than 7 days 3. Respiratory failure not fully explained by cardiac failure or fluid overload 4. Intubation on controlled ventilation and receiving PEEP ≥ 5 cm H2O * Age 16 years or older * Duration of ARDS 36 hours or less from meeting final Berlin criterion.

Exclusion criteria

* Received mechanical ventilation more than 96 hours * Recently treated or bleeding varices, esophageal stricture, hematemesis, esophageal trauma, recent esophageal surgery or other contraindication for nasogastric tube placement * Severe coagulopathy (platelet count \< 5000/microliter or INR \> 4) * History of lung transplantation * Elevated intracranial pressure or conditions where hypercapnia-induced elevations in intracranial pressure should be avoided * Evidence of active air leak from the lung * not committed to full support * Participation in other intervention trials for ARDS or for sepsis within the past 30 days. * Neuromuscular disease that impairs ability to ventilate spontaneously * Severe chronic liver disease, defined as Child-Pugh Score of ≥12 * Treating clinician refusal, or unwillingness to commit to controlled ventilation for at least 24 hours * Inability to get informed consent from the patient or surrogate. * Use of rescue therapies for prior to enrollment (e.g. nitric oxide, ECMO, prone positioning, high frequency oscillation). This does not exclude cases where these therapies were used as the initial mode of ventilation

Design outcomes

Primary

MeasureTime frameDescription
A composite outcome of mortality and time off the ventilator at 28-days.Day 28The trial will utilize a primary composite endpoint that incorporates death and days off the ventilator at 28 days in such a manner that death constitutes a more serious outcome. Every subject is compared to every other subject in the trial and assigned one number resulting from each comparison. Since mortality outcome is clinically more important, mortality takes precedence over days off the ventilator. The sum of scores for patients in the treatment group is compared to the sum of scores of subjects in the control group to form a test statistic by the Mann-Whitney technique.

Secondary

MeasureTime frameDescription
mortalityDay 60Hospital and ICU mortality to day 60
lengths of stayDay 60Hospital and ICU lengths of stay to days 28 and 60
biomarkers of lung injuryDay 7Plasma biomarkers of lung injury on enrollment and days 3 and 7 after enrollment
Survival1 yearMortality to 1 year
Ventilator free days to day 28Day 28Number of calendar days breathing unassisted.
Activities of daily living1 yearWill assess via questionnaire (Barthel Index) done by phone at 1 year. Barthel Index scores range from 0-100, with 100 representing greatest independence of activities of daily living.
Self-reported health assessment1 yearWill assess via questionnaire (12-Item Short-Form Health Survey \[SF-12\]) done by phone at 1 year. The SF-12 scores range from 0-100 points, with higher scores representing the highest level of health.
Frailty in patients age 65 and older1 yearWill assess via questionnaire (Vulnerable Elders-13 Survey) done by phone at 1 year. VES scores range from 0-10 points, with higher scores representing greater risk.
Need for rescue therapyDay 28Rescue measures will be chosen according to the practice at the clinical site, and may include repeated recruitment maneuvers, prone positioning, nitric oxide, epoprostenol sodium, airway pressure release ventilation, high frequency ventilation, or ECMO.

Countries

Canada, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026